Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
about
Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospectsPatient experience in the treatment of metastatic castration-resistant prostate cancer: state of the scienceEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsThe impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewGrowth factor and signaling pathways and their relevance to prostate cancer therapeuticsMedical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantAnti-angiogenesis in prostate cancer: knocked down but not outSystemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223Chemotherapy and its evolving role in the management of advanced prostate cancerEvolving landscape and novel treatments in metastatic castrate-resistant prostate cancerQuo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesRecent progress in pharmaceutical therapies for castration-resistant prostate cancerSequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapyTargeting the adaptive molecular landscape of castration-resistant prostate cancerCirculating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate CancerChemotherapy options in castration-resistant prostate cancerSerine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancerDocetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trialTumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab TherapyThe lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancerMultimodal imaging guided preclinical trials of vascular targeting in prostate cancer.Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapyAn updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancerA randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.Glucocorticoids and prostate cancer treatment: friend or foe?Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Bone-targeting agents in prostate cancer.Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis.Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.Risks and benefits with bevacizumab: evidence and clinical implications.Novel therapies for metastatic castrate-resistant prostate cancer.End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic reviewCritical appraisal of cabazitaxel in the management of advanced prostate cancerLong-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancerA phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer
P2860
Q26770428-DE6ED476-5AD5-4750-9D5E-A06F2A2CB2ECQ26772883-95B88001-07FF-4B26-BC02-574E9B246E37Q26786618-DACFE33C-76F2-4D46-AC1A-CAAF58400E26Q26824086-16601F02-6E91-4B9D-8A31-2F1C76017543Q26827975-F2D7F3B9-BA29-402C-8109-2E6DE8DDBB7EQ26851177-BFAC3B7E-F216-4C32-9F14-CC6FBB1EE532Q26851183-C7ED410E-70FB-41EA-95F0-CAFAEC9A4F36Q26852544-EECD6398-4E65-47F6-985F-D9B36B753E38Q26861575-A96F4D9C-0E20-49EE-8AC0-EC50D3CA072EQ27008883-6F4829A1-41F1-4F34-8C60-41D7BF2AC329Q27010542-75C02091-F3CF-4A7F-9AE9-08CFDE6DB35DQ27011642-D53A1224-C2A0-44D2-B51B-220344D87AC9Q27022567-D048D921-AFEC-4E35-9A67-55F0EA2705B5Q27022715-939A0EA5-B7CA-42CC-9DF7-60D233EDE113Q27022821-F3C5DE89-DF9C-48E7-8F07-A7DD3104D7E7Q27334654-53BB6526-BBBF-4EDC-B1AE-A18BD3BBA378Q28075965-A23F3BE1-4F8B-44E5-9FAA-C780DAC7084AQ28078477-5301FDA1-C392-47A5-A0A6-9846E1835277Q28251240-8571120C-40DD-42B9-95CC-0177DB50CC89Q28294857-E524B32C-C868-4F72-809C-2B2045C0BFDFQ28550733-D74FDC6A-CF9C-41B8-AB3E-10C3958117BAQ28687241-EBF3D11F-54E5-44E7-9A3C-7C8E598CE6D5Q30393012-8B31566E-D048-400F-9584-54C8ADE632B4Q30538388-1446318D-43DD-4B58-832F-FDD83F25044AQ31152878-2AEE14A1-799D-44E0-9DEA-A8D08A8E43C6Q33406047-F3E7B89A-E03A-407F-84F3-65F275CF9BEAQ33415009-FEBC8DE0-A2DC-4E65-A005-71868830B7BAQ33416977-EDE1D2EC-BE99-40EC-9F6B-958ED9C13F4EQ33429309-26457401-94E5-434B-9806-C6962E478827Q33621387-70E244F2-599F-48C2-A97B-E8C2D247CC17Q33770680-342FA103-AE57-45B2-96BC-55ADA37FA9CDQ33864723-36709A31-A329-484B-9C2B-B04B21AB894BQ33904867-F102C875-DC66-4B0E-9179-50562A967548Q33946929-C9B3CFD2-AF40-45EF-9F73-B3B287BE3ACFQ33949406-8EF78388-5A38-40EA-B126-FA110284E3D1Q34249263-0A606D3F-32CE-486F-9793-8DFEF51F8A68Q34367585-D8708CF1-72EF-480E-B1B8-8906F5CE2BFBQ34386577-A5DE88B5-5B5D-4B0C-8C6C-7CC048B25364Q34608976-C14F17D7-7089-4625-A544-F1F716E1176DQ34657338-3E5F4A32-5A26-454C-BFD2-ED961D0DC104
P2860
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Randomized, double-blind, plac ...... prostate cancer: CALGB 90401.
@ast
Randomized, double-blind, plac ...... prostate cancer: CALGB 90401.
@en
type
label
Randomized, double-blind, plac ...... prostate cancer: CALGB 90401.
@ast
Randomized, double-blind, plac ...... prostate cancer: CALGB 90401.
@en
prefLabel
Randomized, double-blind, plac ...... prostate cancer: CALGB 90401.
@ast
Randomized, double-blind, plac ...... prostate cancer: CALGB 90401.
@en
P2093
P2860
P50
P921
P356
P1476
Randomized, double-blind, plac ...... t prostate cancer: CALGB 90401
@en
P2093
Daniel George
Ellen Kaplan
Eric J Small
J Paul Monk
John F Mahoney
Michael Carducci
Nicholas J Vogelzang
Walter M Stadler
William Kevin Kelly
P2860
P304
P356
10.1200/JCO.2011.39.4767
P407
P577
2012-03-26T00:00:00Z